Publication & Citation Trends
Publications
0 total
A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
Cited by 2
Semantic Scholar
Abstract CT153: SDX-7320 elicits improvements in tumor-related and metabolic biomarkers: Results of a phase 1 dose-escalation study in patients with advanced refractory or late-stage solid tumors
Cited by 0
Semantic Scholar
179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy OA
Cited by 2
Semantic Scholar
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. OA
Cited by 58
Semantic Scholar
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.
Cited by 2
Semantic Scholar
Research Topics
Cancer, Lipids, and Metabolism
(15)
Advanced Breast Cancer Therapies
(12)
Cancer, Hypoxia, and Metabolism
(11)
Cancer Treatment and Pharmacology
(10)
Colorectal Cancer Treatments and Studies
(6)
Affiliations
Radius Health (United States)
ImmunoGen (United States)
Mission Bio (United States)
NeuroDevelopment Center
SynDevRx (United States)